What is Indaptus Therapeutics Probability of Financial Distress (%)?
Probability of Financial Distress (%) measures the probability that a company will go bankrupt in the upcoming year given its current financial position. A higher ratio indicates a larger probability of bankruptcy for the company, while a lower ratio indicates a healthier fundamental. As of today, Indaptus Therapeutics's Probability of Financial Distress (%) is 1.26%.
Like the Altman Z-Score, the PFD measures a company's bankruptcy risk. However, the main drawback of the Z-score is it does not apply to banks and insurance companies. According to Investopedia, the concept of "working capital" does not apply to banks and insurance companies, as financial institutions do not have typical current assets or current liabilities like inventories or accounts payable.
Competitive Comparison of Indaptus Therapeutics's Probability of Financial Distress (%)
For the Biotechnology subindustry, Indaptus Therapeutics's Probability of Financial Distress (%), along with its competitors' market caps and Probability of Financial Distress (%) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Indaptus Therapeutics's Probability of Financial Distress (%) Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Indaptus Therapeutics's Probability of Financial Distress (%) distribution charts can be found below:
* The bar in red indicates where Indaptus Therapeutics's Probability of Financial Distress (%) falls into.
Indaptus Therapeutics Probability of Financial Distress (%) Calculation
Probability of Financial Distress (%) (PFD) was developed by John Campbell, Jens Hilscher and Jan Szilagyi in their Search of Distress Risk. It measures the probability that a company will go bankrupt within the next 12 months given its current financial position.
The Probability of Financial Distress (%) was obtained by a logit probability model based on eight explanatory variables. The logit formula to compute the probability of financial distress (LPFD) is given below:
| LPFD | = | -20.12 * NIMTAAVG | + | 1.60 * TLMTA | - | 7.88 * EXRETAVG | + | 1.55 * SIGMA | - | 0.005 * RSIZE | - | 2.27 * CASHMTA | + | 0.070 * MB | - | 0.09 * PRICE | - | 8.87 |
| = | -4.36 |
The Probability of Financial Distress (%) (PFD) was then obtianed by:
| PFD | = | 1 | / | (1 + e^(-LPFD)) | * | 100% |
| = | 1.26% |
The eight explanatory variables are:
1. NIMTAAVG = Net Income to Market Total Assets
*Note that for companies reported quarterly, geometrically declining weighted quarterly Net Income data in latest four quarters are used.
2. TLMTA = Total liabilities to Market Total Assets
3. CASHMTA = Cash to Market Total Assets
For non-financial companies, CASHMTA is measured as:
4. EXRETAVG = Excess Return compared to the S&P 500
EXRETAVG is the weighted excess return compared to the S&P 500 in past 12 month. Geometrically declining weights are imposed on the monthly excess return to reflect lagged information. The weight is halved each quarter.
5. SIGMA = Standard Deviation of Daily Returns
For sigma, we use the annualized standard deviation of a company's returns over the past 92 days (or 63 trading days).
6. RSIZE = Relative Size
| RSIZE | = | log (Market Cap | / | Total Market Cap of S&P 500 companies) |
7. MB = Market to Adjusted Book Equity Ratio
8. PRICE
PRICE is measured as the log of the stock price, capped at log(15).
Indaptus Therapeutics (Indaptus Therapeutics) Business Description
Traded in Other Exchanges
N/A
Address
3 Columbus Circle, 15th Floor, New York, NY, USA, 10019
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma in standard pre-clinical models.
Executives
| Glen R. Anderson |
10 percent owner |
3274 ROSS ROAD, PALO ALTO CA 94303 |
| Roger J. Waltzman |
officer: Chief Medical Officer |
C/O JAGUAR ANIMAL HEALTH, INC., 201 MISSION STREET, SUITE 2375, SAN FRANCISCO CA 94105 |
| Robert Martell |
director |
4 MAGUIRE ROAD, LEXINGTON MA 02421 |
| Boyan Vesselinov Litchev |
officer: Chief Medical Officer |
13357 RUSSET LEAF LN., SAN DIEGO CA 92129 |
| Jeffrey A Meckler |
director, officer: Chief Executive Officer |
740 BROADWAY, 9TH FLOOR, NEW YORK NY 10003 |
| Walt Addison Linscott |
officer: Chief Business Officer |
1860 MONTREAL ROAD, TUCKER GA 30084 |
| Michael James Newman |
director, 10 percent owner, officer: Chief Scientific Officer |
C/O INTEC PARENT, INC., 12 HARTOM ST., HAR HOTZVIM, JERUSALEM L3 9777512 |
| Mark John Gilbert |
director |
13731 NORTHWOOD RD., NW, SEATTLE WA 98177 |
| Brian O'callaghan |
director |
550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921 |
| Hoonmo Lee |
director, 10 percent owner |
C/O INTEC PARENT, INC., 12 HARTOM ST., HAR HOTZVIM, JERUSALEM L3 9777512 |
| Anthony J Maddaluna |
director |
PFIZER INC. ATTN CORPORATE SECRETARY, 235 RAST 42ND STREET, NEW YORK NY 10017 |
| William B Hayes |
director |
231 MAPLE AVENUE, BURLINGTON NC 27215 |
| Roger Pomerantz |
director |
711 HARVEST HILL ROAD, CHALFONT PA 18914 |
| Hila Karah |
director |
9 HALAMISH STREET, CAESAREA INDUSTRIAL PARK, CAESAREA L3 38900 |
| Nir Sassi |
officer: Chief Financial Officer |
3 ELUL STREET, APT. 6, MODIIN L3 7176397 |
Indaptus Therapeutics (Indaptus Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
INDP has been successfully added to your